223 related articles for article (PubMed ID: 23869589)
1. Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67.
Sato-Tadano A; Suzuki T; Amari M; Takagi K; Miki Y; Tamaki K; Watanabe M; Ishida T; Sasano H; Ohuchi N
Cancer Sci; 2013 Oct; 104(10):1380-8. PubMed ID: 23869589
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Gruber G; Greiner RH; Hlushchuk R; Aebersold DM; Altermatt HJ; Berclaz G; Djonov V
Breast Cancer Res; 2004; 6(3):R191-8. PubMed ID: 15084243
[TBL] [Abstract][Full Text] [Related]
3. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
[TBL] [Abstract][Full Text] [Related]
4. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
Kronblad A; Jirström K; Rydén L; Nordenskjöld B; Landberg G
Int J Cancer; 2006 May; 118(10):2609-16. PubMed ID: 16381002
[TBL] [Abstract][Full Text] [Related]
6. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
7. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer.
Kim SJ; Nakayama S; Miyoshi Y; Taguchi T; Tamaki Y; Matsushima T; Torikoshi Y; Tanaka S; Yoshida T; Ishihara H; Noguchi S
Ann Oncol; 2008 Jan; 19(1):68-72. PubMed ID: 17956886
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
[TBL] [Abstract][Full Text] [Related]
9. The role of tumor hypoxia in MUC1-positive breast carcinomas.
Zanetti JS; Soave DF; Oliveira-Costa JP; da Silveira GG; Ramalho LN; Garcia SB; Zucoloto S; Ribeiro-Silva A
Virchows Arch; 2011 Oct; 459(4):367-75. PubMed ID: 21892751
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients.
Dales JP; Garcia S; Meunier-Carpentier S; Andrac-Meyer L; Haddad O; Lavaut MN; Allasia C; Bonnier P; Charpin C
Int J Cancer; 2005 Sep; 116(5):734-9. PubMed ID: 15849727
[TBL] [Abstract][Full Text] [Related]
11. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients.
Peurala E; Koivunen P; Bloigu R; Haapasaari KM; Jukkola-Vuorinen A
Breast Cancer Res Treat; 2012 May; 133(1):179-88. PubMed ID: 21877141
[TBL] [Abstract][Full Text] [Related]
12. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
13. HIF-1α and NOTCH signaling in ductal and lobular carcinomas of the breast.
Ercan C; Vermeulen JF; Hoefnagel L; Bult P; van der Groep P; van der Wall E; van Diest PJ
Cell Oncol (Dordr); 2012 Dec; 35(6):435-42. PubMed ID: 23008060
[TBL] [Abstract][Full Text] [Related]
14. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.
Tovey SM; Witton CJ; Bartlett JM; Stanton PD; Reeves JR; Cooke TG
Breast Cancer Res; 2004; 6(3):R246-51. PubMed ID: 15084248
[TBL] [Abstract][Full Text] [Related]
15. IGF-II mRNA expression in breast cancer: predictive value and relationship to other prognostic factors.
Fiore E; Campani D; Muller I; Belardi V; Giustarini E; Rossi G; Pinchera A; Giani C
Int J Biol Markers; 2010; 25(3):150-6. PubMed ID: 20677165
[TBL] [Abstract][Full Text] [Related]
16. Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance.
Yamaguchi M; Takagi K; Sato A; Miki Y; Miyashita M; Sasano H; Suzuki T
Breast Cancer; 2020 Sep; 27(5):919-928. PubMed ID: 32314182
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical investigation of the angiogenic proteins VEGF, HIF-1α and CD34 in invasive ductal carcinoma of the breast.
Maschio LB; Madallozo BB; Capellasso BA; Jardim BV; Moschetta MG; Jampietro J; Soares FA; Zuccari DA
Acta Histochem; 2014 Jan; 116(1):148-57. PubMed ID: 23899963
[TBL] [Abstract][Full Text] [Related]
19. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related.
Bos R; van Diest PJ; van der Groep P; Shvarts A; Greijer AE; van der Wall E
Breast Cancer Res; 2004; 6(4):R450-9. PubMed ID: 15217513
[TBL] [Abstract][Full Text] [Related]
20. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.
Koda M; Kanczuga-Koda L; Sulkowska M; Surmacz E; Sulkowski S
BMC Cancer; 2010 Jun; 10():320. PubMed ID: 20569445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
